Allakos Inc. (ALLK) has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire Allakos for $0.33 in cash per share of Allakos common stock. A wholly owned subsidiary of Concentra will commence a tender offer by April 15, 2025 to acquire all outstanding shares of Allakos common stock. The merger transaction is expected to close in May 2025.
Closing of the offer is subject to certain conditions, including the tender of Allakos common stock representing at least a majority of the total number of outstanding shares, the availability of at least $35.5 million of cash at closing, and other customary closing conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.